伊马替尼耐药患者中一种无c-ABL外显子7的复发性剪接变体。 - Suppr

Suppr

超能文献

A recurrent splicing variant without c-ABL Exon 7 in Imatinib-resistant patients.

作者信息

Curvo Raphael P M, Zalcberg Ilana R, Scholl Vanesa, Pires Virginia, Moellmann-Coelho Arthur, Moreira Miguel A M

出版信息

Leuk Res. 2008 Mar;32(3):508-10. doi: 10.1016/j.leukres.2007.04.018. Epub 2007 Jun 13.

DOI:10.1016/j.leukres.2007.04.018

PMID:17570524

Abstract

摘要

相似文献

A recurrent splicing variant without c-ABL Exon 7 in Imatinib-resistant patients.伊马替尼耐药患者中一种无c-ABL外显子7的复发性剪接变体。

Leuk Res. 2008 Mar;32(3):508-10. doi: 10.1016/j.leukres.2007.04.018. Epub 2007 Jun 13.

Supplemental results of the detection of splicing variant with c-ABL exon 7 deletion by direct sequencing Comment on "A recurrent splicing variant without c-ABL Exon 7 in Imatinib-resistant patients" by Curvo et al. [Leuk. Res.].通过直接测序检测c-ABL外显子7缺失的剪接变体的补充结果对Curvo等人发表于《白血病研究》的《伊马替尼耐药患者中无c-ABL外显子7的复发性剪接变体》的评论

Leuk Res. 2009 Mar;33(3):505-6. doi: 10.1016/j.leukres.2008.08.024. Epub 2008 Oct 9.

Double Philadelphia-chromosome: a resistance factor on the imatinib mesylate therapy for chronic myeloid leukemia.双费城染色体：甲磺酸伊马替尼治疗慢性粒细胞白血病的一个耐药因素。

Int J Lab Hematol. 2008 Aug;30(4):346-8. doi: 10.1111/j.1751-553X.2007.00957.x.

Imatinib resistance in CML.慢性粒细胞白血病中的伊马替尼耐药性。

Cancer Lett. 2009 Feb 8;274(1):1-9. doi: 10.1016/j.canlet.2008.06.003. Epub 2008 Jul 23.

Chronic myelogenous leukemia progenitors display a genetically unstable personality.慢性粒细胞白血病祖细胞表现出基因不稳定的特性。

J Natl Cancer Inst. 2007 May 2;99(9):662-3. doi: 10.1093/jnci/djk176.

Coexistence of AML1/RUNX1 and BCR-ABL point mutations in an imatinib-resistant form of CML.

Leukemia. 2005 Nov;19(11):1991-2. doi: 10.1038/sj.leu.2403931.

BCR-ABL in chronic myelogenous leukemia--how does it work?慢性粒细胞白血病中的BCR-ABL——它是如何起作用的？

Acta Haematol. 2008;119(4):212-7. doi: 10.1159/000140633. Epub 2008 Jun 20.

Dynamics of BCR-ABL mutated clones prior to hematologic or cytogenetic resistance to imatinib.伊马替尼血液学或细胞遗传学耐药之前BCR-ABL突变克隆的动态变化。

Haematologica. 2008 Feb;93(2):186-92. doi: 10.3324/haematol.11993. Epub 2008 Jan 26.

Imatinib mesylate resistance in a chronic myeloid leukemia patient with a novel e8a2 BCR-ABL transcript variant.一名慢性髓性白血病患者携带新型e8a2 BCR-ABL转录本变体，对甲磺酸伊马替尼耐药。

Acta Haematol. 2008;120(3):146-9. doi: 10.1159/000178145. Epub 2008 Nov 28.

Imatinib resistance in a novel translocation der(17)t(1;17)(q25;p13) with loss of TP53 but without BCR/ABL kinase domain mutation in chronic myelogenous leukemia.慢性粒细胞白血病中一种新的易位der(17)t(1;17)(q25;p13)导致的伊马替尼耐药，伴有TP53缺失但无BCR/ABL激酶结构域突变

Cancer Genet Cytogenet. 2008 May;183(1):77-81. doi: 10.1016/j.cancergencyto.2008.01.024.

引用本文的文献

ABL1 tyrosine kinase domain mutations in chronic myeloid leukemia treatment resistance.ABL1 酪氨酸激酶结构域突变与慢性髓性白血病治疗耐药。

Mol Biol Rep. 2019 Aug;46(4):3747-3754. doi: 10.1007/s11033-019-04816-5. Epub 2019 Apr 25.

BCR-ABL exon 7 deletion and novel point mutation in patient with chronic myelogenous leukemia and TKI resistance.慢性粒细胞白血病且对酪氨酸激酶抑制剂耐药患者的BCR-ABL外显子7缺失及新的点突变

Clin Case Rep. 2018 Sep 14;6(11):2057-2060. doi: 10.1002/ccr3.1794. eCollection 2018 Nov.

[Discovery of a novel spliceosome of ABL gene (ABL(Δexon7+35INS)) and its association with TKIs resistance in chronic myeloid leukemia].[ABL基因新型剪接体（ABL(Δexon7+35INS)）的发现及其与慢性髓性白血病中酪氨酸激酶抑制剂耐药性的关联]

Zhonghua Xue Ye Xue Za Zhi. 2016 Jun 14;37(6):503-6. doi: 10.3760/cma.j.issn.0253-2727.2016.06.012.

Rapid identification of compound mutations in patients with Philadelphia-positive leukaemias by long-range next generation sequencing.通过长片段新一代测序技术快速鉴定费城阳性白血病患者的复合突变。

Eur J Cancer. 2014 Mar;50(4):793-800. doi: 10.1016/j.ejca.2013.11.030. Epub 2013 Dec 20.

Characterization of ABL exon 7 deletion by molecular genetic and bioinformatic methods reveals no association with imatinib resistance in chronic myeloid leukemia.通过分子遗传和生物信息学方法对 ABL 外显子 7 缺失进行的特征分析并未显示其与慢性髓性白血病伊马替尼耐药有关。

Med Oncol. 2012 Sep;29(3):2136-42. doi: 10.1007/s12032-011-0092-9. Epub 2011 Oct 30.

BCR-ABL isoforms associated with intrinsic or acquired resistance to imatinib: more heterogeneous than just ABL kinase domain point mutations?与伊马替尼内在或获得性耐药相关的 BCR-ABL 异构体：比 ABL 激酶结构域点突变更具异质性？

Med Oncol. 2012 Mar;29(1):219-26. doi: 10.1007/s12032-010-9781-z. Epub 2011 Jan 8.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验